NGeneBio Co., Ltd. Logo

NGeneBio Co., Ltd.

Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.

354200 | KO

Overview

Corporate Details

ISIN(s):
KR7354200008
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로 288 303호. 304호. 305호. 306호. 307호. 제지1층 제비 127호, 제지1층 제비 1, 구로구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NGeneBio Co., Ltd. is a biotechnology company specializing in molecular diagnostics (MDx) and companion diagnostics (CDx) based on Next-Generation Sequencing (NGS) technology. The company develops and provides precision diagnostic solutions, including NGS-based panels for oncology (e.g., breast and ovarian cancer), bioinformatics analysis software, and liquid biopsy products. NGeneBio also offers personalized genetic-based healthcare services. As a leading supplier to hospitals in its domestic market, the company is focused on expanding its presence in the global precision medicine field.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 125.6 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.2 MB
2025-08-01 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 124.6 KB
2025-08-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-07-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.8 KB
2025-06-30 00:00
Board/Management Information
대표이사변경
Korean 10.7 KB
2025-06-27 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-06-27 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 60.8 KB
2025-06-27 00:00
Major Shareholding Notification
최대주주인명목회사·조합등의최대주주변경
Korean 15.0 KB
2025-06-26 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 21.7 KB
2025-06-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 15.0 KB
2025-06-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 102.7 KB

Automate Your Workflow. Get a real-time feed of all NGeneBio Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NGeneBio Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NGeneBio Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.